J 2017

F-18-FDG PET/CT in polymyalgia rheumatica-a pictorial review

ŘEHÁK, Zdeněk, Andrea ŠPRLÁKOVÁ-PUKOVÁ, Tomáš KAZDA, Zdeněk FOJTÍK, Lenka VARGOVÁ et. al.

Basic information

Original name

F-18-FDG PET/CT in polymyalgia rheumatica-a pictorial review

Authors

ŘEHÁK, Zdeněk (203 Czech Republic, guarantor, belonging to the institution), Andrea ŠPRLÁKOVÁ-PUKOVÁ (203 Czech Republic), Tomáš KAZDA (203 Czech Republic, belonging to the institution), Zdeněk FOJTÍK (203 Czech Republic, belonging to the institution), Lenka VARGOVÁ (203 Czech Republic, belonging to the institution) and Petr NĚMEC (203 Czech Republic, belonging to the institution)

Edition

BRITISH JOURNAL OF RADIOLOGY, LONDON, BRITISH INST RADIOLOGY, 2017, 0007-1285

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30224 Radiology, nuclear medicine and medical imaging

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.814

RIV identification code

RIV/00216224:14110/17:00098713

Organization unit

Faculty of Medicine

UT WoS

000411905200011

Keywords in English

Polymyalgia rheumatica

Tags

Tags

International impact, Reviewed
Změněno: 18/3/2018 23:06, Soňa Böhmová

Abstract

V originále

Polymyalgia rheumatica (PMR) is one of the inflammatory rheumatic diseases that can potentially be detected by positron emission tomography/CT. High fluorine-18 fludeoxyglucose (F-18-FDG) accumulation around the shoulders, sternoclavicular and hip joints are the most common pre-treatment features of patients with PMR. Another common sign is increased F-18-FDG uptake in extra-articular regions between columnal spinous processes, near ischial tuberosities and in the praepubic area. Some patients also present with high F-18-FDG uptake in main arteries, corresponding to the characteristics of giant cell arteritis. It is possible to observe a decrease or even a disappearance of F-18-FDG uptake after effective therapy, an event which may be useful for the monitoring of treatment as well as for detection of PMR relapse.